AbbVie seeks US, EU approval for Skyrizi for ulcerative colitis
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
178,380$
1,59%
Echtzeit-Aktienkurs Abbvie Inc.
Bid:
Ask:
Nachrichten zur Abbvie Inc. Aktie
AbbVie Submits Applications For New Indication To FDA And EMA For Ulcerative Colitis
WASHINGTON (dpa-AFX) - Biopharmaceutical company AbbVie, Inc. (ABBV) announced Monday that it has submitted applications for a new indication to…
AbbVie Seeks U.S., Europe OK for Skyrizi in Ulcerative Colitis >ABBV
AbbVie Seeks U.S., Europe OK for Skyrizi in Ulcerative Colitis >ABBV...…
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could…
The Zacks Analyst Blog Highlights Procter & Gamble, AbbVie, The Walt Disney, HSBC Holdings and Duke Energy
Procter & Gamble, AbbVie, The Walt Disney, HSBC Holdings and Duke Energy are part of the Zacks top Analyst Blog....…
Top Analyst Reports for Procter & Gamble, AbbVie & Walt Disney
Todays Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Company (PG), AbbVie Inc.…
Can AbbVie (ABBV) Protect Revenues After Humira Patent Loss?
AbbVies (ABBV) newer products, Skyrizi and Rinvoq, are performing extremely well and have the potential to make up for lost…
This Is What Whales Are Betting On AbbVie
read more...…
AbbVie (ABBV) Gets EU Approval for Migraine Prevention Drug
Following the approval, AbbVies (ABBV) Aquipta is the first and the only oral CGRP receptor antagonist approved in the EU…
AbbVie wins EU clearance for migraine therapy
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Is AbbVie Still a Good Dividend Stock to Buy?
Find out if AbbVie can overcome sinking sales of its top-selling product....…
Form 10-Q AbbVie Inc. For: Jun 30
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Is AbbVie Stock a Buy for Income Investors?
The pharmaceutical giant is forecasting a return to growth starting in 2024....…
Corporate News: Temedica GmbH
Temedica launcht in Kooperation mit AbbVie Deutschland einen digitalen Begleiter für PatientInnen mit chronisch-entzündlichen Darmerkrankungen...…
Better High-Yield Dividend Stock: AbbVie vs. Verizon Communications
Which of these high-yield dividend stocks is the better buy right now?...…
Pharma Stock Roundup: AZN, SNY, ABBV Q2 Results, MRK, MRNA Cancer Jab in Phase III
AstraZeneca (AZN), Sanofi (SNY) and AbbVie (ABBV) announce second-quarter results....…
AbbVie (ABBV) Q2 2023 Earnings Call Transcript
ABBV earnings call for the period ending June 30, 2023....…
Why AbbVie Stock Is Jumping Today
Humira isnt the only story for AbbVie these days....…
AbbVie Raises Earnings Outlook as Autoimmune Drugs Come In Strong
Sales of Skyriz and Rinvoq both rose by 50% or more from a year earlier, making up for continuing declines…
Compared to Estimates, AbbVie (ABBV) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter…
AbbVie (ABBV) Beats Q2 Earnings and Revenue Estimates
AbbVie (ABBV) delivered earnings and revenue surprises of 4.30% and 2.54%, respectively, for the quarter ended June 2023. Do the…
Inside AbbVie: Signs of stabilization in Humira sales?
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
AbbVie Boosts FY23 Outlook As Q2 Results Top Estimates
WASHINGTON (dpa-AFX) - While reporting financial results for the second quarter on Thursday, biopharmaceutical company AbbVie, Inc. (ABBV) trimmed its…
AbbVie shares climb after quarterly results beat expectations
AbbVie Inc. ABBV shares gained 1.5% premarket on Thursday after the pharmaceutical giant reported stronger-than-expected revenue for the second quarter…
AbbVie Q2 Profit Increases, beats estimates
WASHINGTON (dpa-AFX) - AbbVie (ABBV) released a profit for its second quarter that increased from last year and beat the…
Form 8-K AbbVie Inc. For: Jul 27
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
AbbVie raises annual profit forecast as Humira stays strong, new drugs impress
...(Reuters) - AbbVie on Thursday raised its annual profit forecast......…
AbbVie Non-GAAP EPS of $2.91 beats by $0.10, revenue of $13.87B beats by $350M
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
AbbVie may see less pain from Humira sales decline as rival lags
...By Leroy Leo
(Reuters) - AbbVie Inc is likely to beat Wall......…
PREVIEW-AbbVie may see less pain from Humira sales decline as rival lags
...By Leroy Leo
July 26 (Reuters) - AbbVie Inc is likely to
beat Wall......…
AbbVie under pressure ahead of Q2 results amid Humira cliff
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
AbbVie expands collaboration with Calibr on early-stage assets
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Seven Humira Biosimilars: Increased Competition In Arthritis Drug Market Sparks Need For Reform Of Drug Pricing Intermediaries
Seven pharmaceutical companies recently launched their biosimilars of AbbVie Inc's (NYSE: ABBV) top-selling read more...…
The Zacks Analyst Blog Highlights Toyota, Deere, Starbucks, AbbVie and DexCom
Toyota, Deere, Starbucks, AbbVie and DexCom are included in this Analyst Blog....…
Earnings Previews: AbbVie, Comcast, Valero Energy
Before U.S. markets open on Thursday, these three firms will be reporting quarterly results....…
AbbVie turns to newer immunology drugs as blockbuster Humira faces lower-cost competition
Investors look for signs that Skyrizi, Rinvoq can take the baton as Humira sales falter...…
Zacks Investment Ideas feature highlights: Chipotle Mexican Grill, Visa and AbbVie
Chipotle Mexican Grill, Visa and AbbVie have been highlighted in this Investment Ideas article....…
Übernahme von Botox-Hersteller gibt AbbVie Schub
Frankfurt (Reuters) - Der US-Pharmakonzern AbbVie profitiert von einer hohen Nachfrage nach seinem Blockbuster-Medikament Humira und der Übernahme des Botox-Herstellers…
Agentur - Boehringer und AbbVie in Gesprächen über Krebs-Allianz
Bangalore (Reuters) - Deutschlands zweitgrößter Pharmakonzern Boehringer Ingelheim steht einem Agenturbericht zufolge vor einer umfassenden Partnerschaft bei Krebs-Therapien mit dem…